DaVita Venture Group

DaVita Venture Group, founded in 2020 and based in Denver, Colorado, serves as the investment arm of DaVita Inc. It focuses on building partnerships with healthcare innovators to enhance the lives of patients with kidney disease. The group aims to invest in, develop, and launch products and solutions that improve care for kidney disease and related conditions. DaVita Venture Group targets early-stage and later-stage companies in key areas, including digital health, pharmaceuticals, medical devices, and care delivery models. By leveraging technology and data, the firm seeks to transform healthcare delivery, expand access to care, and improve clinical outcomes while reducing costs within the healthcare system.

Amanda Kovach

Director, Partnerships and Corporate Development

10 past transactions

Pathalys Pharma

Series B in 2024
Pathalys Pharma is a biopharmaceutical company dedicated to developing therapeutics for late-stage chronic kidney diseases. Its primary focus is improving treatment for secondary hyperparathyroidism, an unmet need in healthcare.

Xeltis

Series D in 2023
Xeltis is a clinical-stage medical device company developing bio-absorbable heart valves and blood vessels. Its RestoreX technology enables the body's natural healing system to create functional tissue within its devices, forming new valves or vessels over time. Headquartered in Zurich, Switzerland, with R&D and manufacturing facilities in Eindhoven, Netherlands, Xeltis aims to transform cardiovascular care.

Dock Health

Seed Round in 2023
Dock Health is a Boston-based company established in 2016 that develops a HIPAA-compliant task management and collaboration platform specifically for the healthcare sector. The company aims to address significant workflow challenges and inefficiencies faced by clinicians and their teams by providing a reliable and secure system for communication and task management. Through its thoughtfully designed platform, Dock Health empowers healthcare professionals across various settings and specialties to enhance collaboration, ultimately improving patient care. By streamlining processes and facilitating effective teamwork, Dock Health is committed to transforming the organizational and operational dynamics of healthcare providers.

Xeltis

Series D in 2023
Xeltis is a clinical-stage medical device company developing bio-absorbable heart valves and blood vessels. Its RestoreX technology enables the body's natural healing system to create functional tissue within its devices, forming new valves or vessels over time. Headquartered in Zurich, Switzerland, with R&D and manufacturing facilities in Eindhoven, Netherlands, Xeltis aims to transform cardiovascular care.

Pathalys Pharma

Series A in 2023
Pathalys Pharma is a biopharmaceutical company dedicated to developing therapeutics for late-stage chronic kidney diseases. Its primary focus is improving treatment for secondary hyperparathyroidism, an unmet need in healthcare.

Pathalys Pharma

Seed Round in 2021
Pathalys Pharma is a biopharmaceutical company dedicated to developing therapeutics for late-stage chronic kidney diseases. Its primary focus is improving treatment for secondary hyperparathyroidism, an unmet need in healthcare.

Heartbeat Health

Series B in 2021
Heartbeat Health, Inc. is a healthcare technology company based in New York that specializes in cardiology services. Founded in 2017, it provides virtual-first solutions for the prevention and management of cardiovascular disease. The company utilizes a data-powered platform to facilitate real-time consultations between patients and physicians, enabling secure communication and collaboration on treatment and dietary advice. By offering tools that allow patients to monitor their heart health, Heartbeat Health aims to reduce cardiovascular risk and the likelihood of adverse health events. Its comprehensive approach enhances patient care and supports at-risk organizations through a focus on higher-value healthcare delivery.

Nephrosant

Series A in 2021
NephroSant is an innovative diagnostic startup established by a team of physicians and experts in science, engineering, and clinical research, dedicated to enhancing global kidney health. The company has developed a urine-based diagnostic tool that enables the quantitative measurement of biomarkers crucial for the early detection and ongoing monitoring of kidney disease. This noninvasive tool is particularly valuable for physicians, as it aids in predicting and preventing the progression of kidney disease and facilitates the early detection of acute rejection in kidney transplant patients. Through their research-driven approach, NephroSant aims to significantly improve patient outcomes in kidney health.

SameSky Health

Series B in 2020
SameSky Health specializes in multicultural patient engagement solutions. Its platform connects payers, providers, and health systems with diverse Medicare populations, offering multi-channel messaging, care navigation, data insights, and consultancy services to enhance engagement, reduce emergency room visits, and improve healthcare outcomes.

Wellth

Series A in 2020
Wellth operates a mobile application that engages consumers in managing chronic diseases and fostering healthy habits. By providing targeted incentives, reminders, and information, Wellth aims to reduce healthcare costs by encouraging preventative actions and disease management.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.